At the San Antonio Breast Cancer Symposium 2024, Maria Vittoria Dieci presented key findings from the A-BRAVE trial, shedding light on the role of avelumab in high-risk triple-negative breast cancer (TNBC). Her research explores the impact of PD-L1 expression, tumor-infiltrating lymphocytes (TILs), and residual cancer burden (RCB) on treatment outcomes, providing critical data for improving patient care.
These findings mark a significant step forward in personalized immunotherapy, reinforcing the potential of biomarker-driven treatment strategies in breast cancer.
Thanks to Maria Vittoria Dieci and all the researchers for their dedication to advancing breast cancer research and improving outcomes for patients worldwide.
